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ST-elevation Myocardial Infarction
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Background/Purpose: Knowledge concerning subacute stent thrombosis (SST) following primary stent-
ing for ST-elevation myocardial infarction (STEMI) is not widely available. We studied the incidence, pre-
dictors, and clinical outcomes of SST following STEMI.
Methods: We analyzed data from 455 consecutive patients who underwent primary stenting for STEMI.
Baseline clinical characteristics, coronary angiographic features, medication and outcome were compared
in patients with and without SST.
Results: SST occurred in 17 patients, and the incidence was 3.7%. Univariate predictors of SST were being
a current smoker (53.0% vs. 82.4%, p = 0.01), Killip class ≥ II (38.4% vs. 58.8%, p = 0.05), no coronary re-
flow after stenting (6.2% vs. 17.6%, p = 0.05) and lack of coprescription with a statin (39.5% vs. 5.9%,
p < 0.01). After multivariate analysis, being a current smoker (odds ratio = 4.76; 95% confidence inter-
val = 1.20–18.95) and using statin therapy (odds ratio = 0.09; 95% confidence interval = 0.01–0.75) were
independent correlates of SST. Patients with SST were associated with higher 30-day mortality (37.5% vs.
3.1%, p < 0.01) and all-cause mortality (23.5% vs. 5.3%, p = 0.01) at long-term follow-up.
Conclusion: Although SST is rare in patients with STEMI treated by primary stenting, it imparts a signifi-
cantly higher mortality at short-term and long-term follow-up. Being a current smoker and the lack of co-
prescription with a statin were associated with higher incidence of SST. Our results suggest initiation of
statin therapy in patients with STEMI should be considered before discharge.
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In contrast with percutaneous transluminal coro-
nary angioplasty, routine stent implantation for
patients with ST-elevation myocardial infarction
(STEMI) has been shown to reduce the incidence
of target vessel revascularization within 30 days
follow-up and to improve late clinical outcomes.1–3
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Despite the high procedure success rate, stent
placement has its own complications. Subacute
sent thrombosis (SST) following primary stent-
ing for STEMI is an infrequent, complicated phe-
nomenon of concern to physicians and is
associated with high morbidity and mortality.4,5
Recently, there have been many changes in phar-
macological therapy, stent devices and surgical
skills in percutaneous coronary intervention (PCI)
for STEMI. Thus it is possible that the incidence,
predictors and clinical outcomes may be differ-
ent from those reported in previous studies. We
report our experience of SST following primary
stenting for STEMI in 590 consecutive patients.
Methods
Patient characteristics
From January 2000 to December 2006, 590 pa-
tients underwent primary PCI for STEMI in our
institution. The diagnosis of STEMI was defined
as at least two of the following criteria: (1) a typical
chest pain lasting at least 20 minutes; (2) serum
enzyme elevation at least twice the upper limit of
normal; (3) typical electrocardiogram evolving
change, including ST segment elevation of 1 mm
or more with subsequent evolution of negative
T-waves with a depth of 1 mm or more, and evo-
lution of new Q-waves of at least 0.04 seconds in
duration or deeper than one fourth of the follow-
ing R-wave in voltage. For evaluation of the peak
serum cardiac biomarker activity, blood samples
were obtained every 6 hours for 48 hours or until
the activity returned to normal. The reference val-
ues for creatine kinase and creatine kinase(CK)-
MB were 26–192 IU/L and 7–25 IU/L, respectively.
After informed consent, all patients underwent
coronary angiography to confirm the diagnosis
and for therapeutic intervention. We compared
baseline clinical and angiographic characteristics
of the study patients with and without SST and
assessed independent correlates of SST. Clinical
follow-up variables, including unstable angina that
required repeat PCI within 1 year, recurrent myo-
cardial infarction and all-cause mortality, were
obtained at clinic visits, by telephone conversation
and chart review.
Definition of SST
Stent thrombosis is classified by the Academic
Research Consortium as definite, probable, or pos-
sible and as acute (≤ 1 day), subacute (1–30 days),
late (31–360 days), or very late (> 360 days). The
definition of definite stent thrombosis required
the presence of an acute coronary syndrome with
angiographic evidence of thrombosis or occlu-
sion of the study stented segment, including the
5-mm proximal and distal margin, which pre-
ceded stent thrombosis. Probable stent throm-
bosis was defined as unexplained deaths within
30 days and possible stent thrombosis included
all unexplained deaths occurring at least 30 days
after the index procedure.6 To identify the relation-
ship of coronary angiographic features and stent
size with the incidence of SST, only patients with
definite stent thrombosis confirmed by coronary
angiography were included in the present study.
Cardiac catheterization
All patients received the percutaneous transfemoral
approach via an angiography sheath, and stan-
dard angioplasty technique was used in these pa-
tients.7,8 Each patient was pretreated with oral
acetylsalicylic acid (300 mg), clopidogrel (300 mg)
and intravenous heparin (100 U/kg) at the begin-
ning of the procedure, and an additional bolus
of heparin was administered to maintain acti-
vated clotting time > 300 seconds. Judgment of
vessel flow was according to the Thrombolysis In
Myocardial Infarction flow grade. Angiography
stenosis was defined as a diameter reduction of
≥ 50%. If stent implantation was needed, intra-
venous heparin infusion was restarted after stent-
ing and was adjusted to maintain the activated
partial thromboplastin time at 60–85 seconds
for 48 hours. Successful angioplasty was defined
as a target vessel at the treatment site with less
than 20% residual stenosis and Thrombolysis In
Myocardial Infarction 3 flow.
Administration of platelet glycoprotein IIb/
IIIa-receptor inhibitor was left to the clinician’s
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discretion. Post-procedure, all patients were treated
with oral acetylsalicylic acid (100 mg) and clopi-
dogrel (75 mg) daily for at least 1 month.
Statistical analysis
Statistical analyses were performed with SPSS
version 13.0 (SPSS Inc. Chicago, IL, USA). Quanti-
tative data are expressed as mean ± standard devi-
ation. The χ2 test with Yates’ correction or Fisher’s
exact test was used to analyze nonparametric data.
If the frequency of any cell was < 5, then a Fisher
exact test was used. Multivariate analysis was per-
formed with logistic regression to determine the
independent predictors of SST. The selection of
variables was restricted to those that were a priori
identified as relevant based on clinical experience
and variables with a p value less than 0.1 in the
univariate model. A significant odds ratio (OR)
was obtained if the 95% confidence interval (CI)
exceeded 1 and the p value was less than 0.05.
p < 0.05 was considered statistically significant.
Kaplan-Meier analysis was used to create survival
curves for the cumulative incidence of death during
follow-up. Log-rank p-test was used to compare
survival curves between SST and no-SST groups.
Results
Patients
From January 2000 to December 2006, a total of
590 consecutive patients with STEMI were ad-
mitted for primary PCI (Figure 1). After coronary
angiography, 486 patients received stent implan-
tation, while 92 (16%) received balloon angio-
plasty alone and the remaining 12 (2%) did not
receive further intervention. Failure to pass the
guide wire (7 patients), urgent coronary artery
bypass grafting (2 patients), cardio-pulmonary-
cerebral resuscitation and death during coronary
angiography (2 patients) and self-recanalization
of infarct-related artery occurred (1 patient) were
reasons why no further intervention was admin-
istered. Of the 486 patients receiving stent implan-
tation, 36 patients were excluded because of
incomplete follow-up or having expired within 1
month after the index stent implantation. Finally,
455 patients, comprising 384 males and 71 fe-
males with a mean age of 60.5 years (range, 30–91
years), were included. Seventeen patients had def-
inite SST confirmed by coronary angiography,
and the incidence of SST was 3.7%. All the study
590 patients with STEMI,
years 2000–2006
Coronary angiography
17 (3.7%) patients has SST
486 patients received
primary stenting
455 (77%) patients received primary stenting with follow-up at least 1 month
12 (2%) patients
without intervention
–7 failed PCI
–2 CABG
–2 CPCR
–1 self-recanalization
31 (5%) excluded patients
 –6 lost to follow-up within 1 month
 –25 expired within 1 month
  20 refractory cardiogenic shock
  3 sepsis
  2 gastrointestinal bleeding
  1 during CABG
96 (16%) patients received
balloon angioplasty alone
Figure 1. Study patient enrollment. STEMI = ST-segment elevation myocardial infarction; PCI = percutaneous coronary interven-
tion; CABG = coronary artery bypass graft; CPCR = cardio-pulmonary-cerebral resuscitation; SST = subacute stent thrombosis.
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patients received bare metal stents. None of pa-
tients in the study discontinued dual anti-platelet
therapy prematurely. Patient characteristics are
presented in Tables 1 and 2.
Patients with SST
Of the 17 patients with SST, eight patients (47.1%)
presented within the first week, four (23.5%)
during the second week and five (29.4%) during
the third or fourth week after index stent implan-
tation (Table 3). The mean time to SST was 11.2 ±
8.7 days. Sixteen (94.1%) patients with SST pre-
sented as myocardial reinfarction and one (5.9%)
as unstable angina. All the patients with SST in
our study had reocclusion of the stent in the 
infarct-related vessel confirmed by coronary 
angiography. These vessels included the left ante-
rior descending in 13 patients (76.5%), the left
circumflex in one patient (5.9%) and right coro-
nary artery in three patients (17.6%).
Predictors of SST following primary 
stenting for STEMI
The differences in the patient characteristics with
or without SST are described in Tables 1 and 2.
Univariate analysis demonstrated that patients
with SST had a significantly higher incidence of
current smoking, Killip class ≥ II at presentation,
no coronary reflow after stenting, and lack of co-
prescription with a statin compared with those
without SST. Logistic regression analysis demon-
strated that being a current smoker (OR = 4.76;
95% CI = 1.20–18.95), and statin therapy (OR =
0.09, 95% CI = 0.01–0.75) were independent cor-
relates with SST following primary stenting for
STEMI (Table 4).
Table 1. Comparison of patient characteristics between those with and without subacute stent thrombosis*
All patients (n = 455) No SST (n = 438) SST (n = 17) p
Age (yr) 60.5 ± 12.2 60.5 ± 12.3 60.7 ± 11.5 0.94
Sex, male 384 (84.4) 368 (84.0) 16 (94.1) 0.22
BMI (kg/m2) 25.7 ± 3.9 25.7 ± 3.8 26.1 ± 4.7 0.72
Hypertension 252 (55.4) 241 (55.7) 11 (64.7) 0.22
Diabetes mellitus 139 (30.5) 131 (29.9) 8 (47.1) 0.07
Current smoker 246 (54.1) 232 (53.0) 14 (82.4) 0.01
Heart failure 43 (9.5) 39 (8.9) 4 (23.5) 0.06
COPD 19 (4.2) 17 (3.9) 2 (11.8) 0.15
LVEF ≤ 50% 102 (22.4) 98 (22.4) 4 (23.5) 0.56
Presentation
Typical angina 399 (87.9) 385 (88.1) 14 (82.4) 0.34
Killip class ≥ II 178 (39.1) 168 (38.4) 10 (58.8) 0.05
WBC10,000/μL 255 (56.0) 245 (55.9) 10 (58.8) 0.41
Hb10 mg/dL 10 (2.2) 10 (2.3) 0 (0) 0.68
Creatinine ≥ 1.4 mg/dL 102 (22.4) 98 (22.4) 4 (23.5) 0.55
CK (IU/L) 2764.9 ± 2240.7 2761.9 ± 2227.1 2845.1 ± 2667.0 0.88
CK-MB (IU/L) 257.4 ± 195.8 258.5 ± 196.5 228.2 ± 178.9 0.54
T-CHO > 160 (mg/dL) 333 (74.5) 319 (74.0) 14 (87.5) 0.18
TG > 150 (mg/dL) 145 (32.4) 139 (32.2) 6 (37.5) 0.33
HDL < 40 (mg/dL) 117 (42.4) 113 (42.3) 4 (44.4) 0.58
LDL > 100 (mg/dL) 299 (73.0) 194 (73.2) 6 (66.7) 0.46
*Data presented as n (%) or mean ± standard deviation. SST = Subacute stent thrombosis; BMI = body mass index; CK = creatine ki-
nase; COPD = chronic obstructive pulmonary disease; Hb = hemoglobin; HDL = high-density lipoprotein; LDL = low-density lipoprotein;
LVEF = left ventricular ejection fraction; T-CHO = total cholesterol; TG = triglyceride; WBC = white blood cell.
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Outcome of SST
Among those who developed SST following pri-
mary stenting, three patients died because of car-
diogenic shock at 2, 10 and 17 days after the SST
event, respectively. The 30-day mortality of pa-
tients with SST was higher than that of those with-
out SST (37.5% vs. 3.1%, p<0.01, Table 2). During
mean follow-up periods of 37.8 ± 26.1 and 29.0 ±
25.9 months (p = 0.17) in patients with and with-
out SST, respectively, there were no differences 
between the two groups in rates of unstable angina
that required repeat PCI in 1 year (31.3 % vs. 29.4,
p=0.45) and recurrent myocardial infarction (3.4%
vs. 0%, p = 0.56). However, patients with SST had
higher all-cause mortality than those without SST
at clinical follow-up (23.5% vs. 5.3%, p = 0.01).
Using Kaplan Meier analysis, the survival rate was
significantly lower in the group with SST (p <
0.001 by log-rank test, Figure 2) than in those
without.
Table 2. Angiographic characteristics, medication and outcome of the study patients and comparisons
between those with or without subacute stent thrombosis*
All patients (n = 455) No SST (n = 438) SST (n = 17) p
Door to balloon time (min) 95.8 ± 32.1 97.5 ± 32.7 97.5 ± 32.7 0.87
Coronary angiographic features
Multiple-vessel disease 300 (65.9) 289 (66.0) 11 (64.7) 0.45
Total occlusion 330 (72.5) 320 (73.1) 10 (58.8) 0.11
Infarct-related vessel 0.57
LAD 258 (56.7) 245 (55.9) 13 (76.5)
LCX 34 (7.5) 33 (7.5) 1 (5.9)
RCA 160 (35.2) 157 (35.8) 3 (17.6)
Left main 1 (0.2) 1 (0.2) 0 (0)
Intermediate artery 2 (0.4) 2 (0.5) 0 (0)
Stent diameter (mm) 3.1 ± 0.5 3.1 ± 0.5 3.0 ± 0.6 0.19
Stent length (mm) 21.8 ± 7.7 21.9 ± 7.7 18.8 ± 5.5 0.10
No reflow 30 (6.6) 27 (6.2) 3 (17.6) 0.05
Medication
Heparin 444 (97.6) 428 (97.7) 16 (94.1) 0.35
Glycoprotein IIb/IIIa receptor 50 (11.0) 47 (10.7) 3 (18.8) 0.25
inhibitor
Nitrates 141 (31.0) 134 (30.6) 7 (41.2) 0.18
β-Blockers 156 (34.3) 148 (33.8) 8 (47.1) 0.14
Calcium antagonists 12 (2.6) 11 (2.5) 1 (5.9) 0.37
ACEI/ARB 298 (65.5) 286 (65.3) 12 (70.6) 0.34
Statin 174 (38.2) 173 (39.5) 1 (5.9) < 0.01
Acetylsalicylic acid 426 (93.6) 409 (93.4) 17 (100) 0.32
Clopidogrel 378 (83.1) 362 (82.6) 16 (94.1) 0.19
Outcome
Death in 30 d 17 (3.7) 14 (3.1) 3 (37.5) < 0.01
Repeat PCI in 1 yr 142 (31.2) 137 (31.3) 5 (29.4) 0.45
Recurrent MI 15 (3.3) 15 (3.4) 0 (0) 0.56
All-cause mortality 27 (5.9) 23 (5.3) 4 (23.5) 0.01
Follow-up (mo) 37.5 ± 26.2 37.9 ± 26.1 27.6 ± 26.8 0.11
*Data presented as n (%) or mean ± standard deviation. ACEI = Angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor
blocker; LAD = left anterior descending artery; LCX = left circumflex artery; MI = myocardial infarction; PCI = percutaneous coronary in-
tervention; RCA = right coronary artery; SST = subacute stent thrombosis.
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Discussion
The present study assessed the incidence, risk fac-
tors and outcomes of angiography-proven SST in
a cohort of STEMI patients undergoing primary
stenting. SST after STEMI treated with primary
stenting is relatively rare. Previous studies had
shown that 0.4–4.1% of patients had SST after
primary PCI for STEMI.2–4,9,10 The incidence 
of SST in the present study was 3.7%. Our study
appeared to have a similar incidence of SST as
compared with previous studies.
The etiology of SST is multifactorial. Clinical
variables associated with SST reported in previ-
ous studies include an emergently placed stent,
stent malposition, the use of a longer stent, in-
travascular thrombus, Killip classification on 
admission, and left ventricular systolic dysfunc-
tion.5,9–13 In the present study, being a current
smoker, Killip class ≥ II on admission, no coronary
reflow after stent implantation and lack of copre-
scription of statin therapy were associated with a
probability of SST following primary stenting for
STEMI. By using logistic regression analysis, cur-
rent smoker and no use of statins were indepen-
dent predictors for SST. To our knowledge, the
present study is the first to show that statin ther-
apy could prevent SST following primary stent-
ing during STEMI. Most previous studies have
not provided the data of statin therapy for their
patient groups.5,9–13
Smoking is a well-known preventable risk fac-
tor for coronary artery disease.14 Although the
exact pathophysiology of smoking has not been
well described, smoking produces superoxide an-
ions, reduces production of nitric oxide, and causes
endothelial dysfunction, platelet retention and
p < 0.001
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Figure 2. Survival curve produced by Kaplan Meier analy-
sis. Cumulative survival was significantly higher in the
group without subacute stent thrombosis (SST; p < 0.001
by log-rank test).
Table 3. Characteristics of the patients with
subacute stent thrombosis*
Frequency (%)
Patients without SST 438 (96.3)
Patients with definite SST 17 (3.7)
Length of index hospital stay, 
mean (d)
Time to SST 9.9 ± 4.7
Within 1st wk 8 (47.1)
Within 2nd wk 4 (23.5)
Within 3rd and 4th wk 5 (29.4)
Mean (d) 11.2 ± 8.7
Presentation of SST
Recurrent myocardial infarction 16 (94.1)
Unstable angina 1 (5.9)
Infarct-related vessel
LAD 13 (76.5)
LCX 1 (5.9)
RCA 3 (17.6)
*Data presented as n (%) or mean± standard deviation. LAD= Left
anterior descending artery; LCX= left circumflex artery; RCA= right
coronary artery; SST = subacute stent thrombosis.
Table 4. Multivariate analysis of subacute stent
thrombosis
Odds ratio 95% CI p
Age (yr) 1.00 0.96–1.05 0.87
Sex, male 2.70 0.28–25.99 0.39
Killip class ≥ II 2.06 0.71–5.96 0.18
Diabetes mellitus 2.45 0.67–8.93 0.10
Heart failure 2.45 0.67–8.93 0.17
Current smoker 4.76 1.20–18.95 0.03
Statin use 0.09 0.01–0.75 0.03
CI = Confidence interval.
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adhesion that subsequently cause arterial throm-
bosis.15,16 By means of comparison with non-
smokers, Rea et al demonstrated that smoking
was associated with an elevated risk for recurrent
coronary events after incident myocardial infarc-
tion.17 Also, in the present study, patients with SST
had higher prevalence of current smoking habits
compared with those without SST.
After primary stenting for STEMI, intravascular
stents are metallic and thrombogenic.13 Addition-
ally, Sianos et al emphasized that large thrombus
burden during STEMI increased risk of stent throm-
bosis.18 Therefore, instead of proper stent deploy-
ment, intense anticoagulation and antiplatelet
therapy were needed in prevention of more throm-
bus formation after primary stenting for STEMI.
Furthermore, the statin-associated pleiotropic ef-
fects, independent of its lipid-lowering effect, have
been described to reduce plaque thrombogenic-
ity, improve endothelial function, and inhibit
vascular inflammatory response and free-radical
production in the vascular wall.19 Thus we believe
that early coprescription of statin therapy might
play an additional role in protection of patients
with STEMI from developing more thrombus for-
mation and thereby decrease the prevalence of
SST in the present study. Rondina et al also demon-
strated that early statin therapy in patients with
STEMI reduced the risk of adverse cardiovascular
events in the weeks and months following index
myocardial infarction.20 Furthermore, guidelines
from the American College of Cardiology and the
American Heart Association recommended that
patients with STEMI should be treated earlier
with statin therapy before discharge.21,22 However,
only about 40% of the study patients received
statin therapy before discharge from the index
hospitalization, whereas up to 70% of the study
patients had dyslipidemia. Early statin therapy in
patients with STEMI is still underused in clinical
practice, which might be due to lack of awareness,
inertia of previous practice and limitation of re-
imbursement guidelines used by the national
Bureau of National Health Insurance.23
In the present study, about half of the patients
developed SST more than 1 week after the index
stent implantation. It was usually impossible to
rapidly restore coronary arterial flow because pa-
tients had been discharged from the hospital
during the development of SST. In the Primary
Angioplasty in Acute Myocardial Infarction stud-
ies, 1-month reinfarction was independently pre-
dictive of death and revascularization at 6 months.5
In the present study, there was no significant dif-
ference in repeat PCI and reinfarction between pa-
tients with and without SST. However, we found
SST to be strongly associated with increased mor-
tality rates at short-term and long-term follow-up.
The present study has shown that patients
with SST had higher 30-day and all-cause mortality
rates during clinical follow-up. The pleiotropic
effects of statin therapy might provide protection
from SST in those receiving primary stenting for
STEMI. Recent studies have demonstrated cardio-
vascular morbidity and mortality benefits in pa-
tients with acute coronary syndrome who were
prescribed with statin therapy within hours to
days of their events.20 However, statin therapy dur-
ing the index hospitalization is still underused in
real world practice. Clinical physicians should be
aware of this information, and early statin ther-
apy might be considered in patients with STEMI
prior to hospital discharge.
There were several limitations in this study.
First, this was a retrospective analysis, which may
have inherent shortcomings. Second, smoking
status was based on patients’ self report as docu-
mented in medical records and was not verified
by biochemical assay. Our finding may underes-
timate the rate of smoking that attenuated the ac-
curacy of association between smoking and risk
for recurrent coronary events. Third, it is possible
that some patients visited other hospitals due to
SST and were missed by our hospital record review.
Furthermore, we obtained angiographic follow-
up only in those patients who returned with acute
coronary syndrome. The incidence of SST may be
underestimated, because SST could occur silently.
Fourth, β-blockers, as well as statins, were under-
used in the present study, which may have influ-
enced the outcome of the patients. Finally, the
present study was performed before drug-eluting
Subacute stent thrombosis after STEMI
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stents were widely used in patients with STEMI, be-
cause drug-eluting stents might alter the incidence
of SST. However, recent studies had shown that
there were no differences in the incidence of SST
between patients receiving drug-eluting stents and
non-coated stents for myocardial infarction.24,25
In summary, SST in the era of primary stent-
ing for STEMI is rare. However, patients with SST
following primary stenting for STEMI have sig-
nificant higher mortality rate at short-term and
long-term follow-up. We found that being a cur-
rent smoker and the lack of coprescription with a
statin were associated with higher SST risk. Statin
therapy, which is still underused in clinical prac-
tice, might be considered in patients with STEMI
prior to hospital discharge.
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